Posts found in:
Grantees

Reducing inflammation in MPN’s: molecular mechanisms and testing potential  disease modifying therapies MPNs are a group of chronic, progressive blood cancers that reduce life expectancy and quality of life. MPN patients have limited therapeutic options, all implying risk. In this project, we will study a risk-free, food-based approach to decrease inflammation in MPNs and test […]

Pilot trial of Telehealth Music Therapy for Cognitive Dysfunction in Hematologic Cancer Survivor Lymphoma, leukemia, and myeloma survivors often experience difficulties with attention and memory after receiving cancer therapies. Unfortunately, treatments for cognitive issues are limited. The PRELUDE study is a randomized controlled trial that will test the feasibility and effects of music therapy for […]

The role of inflammation during STAG-2 mutant MDS and AML initiation and progression Although we know that cohesin mutations cause myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), we currently cannot target these mutations in a specific manner. My project will identify unique vulnerabilities in cohesin-mutant MDS and AML with the goal to develop less […]

Modulating UBA 1 to treat Myelodysplastic Syndrome Myelodysplastic syndrome (MDS) is a common blood cancer which is caused by genetic mutations. Our lab has identified a new genetic driver of MDS, UBA1, and here we propose to study why these mutations cause disease and how to reverse these defects to help patients.

The Epigenetic Mechanism of Vitamin C in Tumor Suppression Low vitamin C (VC) intake is linked to increased lymphoma risk. However, how VC prevents cancers is unclear. We hypothesize that VC protects our epigenome, which affects how our DNA is read, and helps turn on cancer-suppressing genes. We will identify the proteins that partner with […]

Targeting SLAMF7 using Chimeric Antigen Receptor T-cell Therapy and HMGA1 in Myelofibrosis We propose a novel approach to treating myelofibrosis, a fatal blood cancer, using chimeric antigen receptor (CAR) T-cells. We will study the effects of inhibiting fibrosis-inducing cells with CAR T-cells in mouse models with and without HMGA1 insufficiency. Data from this study will […]

Dissecting MYC Influence on mRNA Processing and  Protein Translation During Acute Myeloid Leukemia Initiation Therapeutic options for patients with Acute Myeloid Leukemia (AML) remain limited, and relapse is common. No studies have addressed the cellular and molecular consequences of MYC overexpression and mutations in AML. Through in-vitro and in-vivo experiments in genetically engineered mouse models, […]

Investigating the role of oncogenic dependency in NPM1-mutant  AML The NPM1 gene is mutated in 20-35% of acute myeloid leukemias (AML). However, it is unclear how mutant NPM1 drives leukemia development and whether the imparted cellular changes are reversible. This proposal aims to define the cellular consequences of mutant NPM1 and whether loss/inhibition of NPM1 […]

Project Title: Therapeutic use of HDL to enhance the anti-leukemia effects of allo-HCT while preventing GvHD Project Description: Clinical goal of bone marrow transplantation (BMT) is to enhance anti-leukemia effects of BMT while preventing its major side effect, graft-versus-host disease (GvHD). We have identified gene products that are modulated by HDL, the good cholesterol, as […]

Project Title: Developing genomic biomarkers for multiple myeloma and T-cell immunotherapy from cell-free DNA Project Description: Multiple myeloma (MM) is the second most common blood cancer. While new treatments have emerged for MM in the last decade, tests to diagnose MM have not changed. We will develop ‘liquid biopsies’ to diagnose, detect, and study MM, […]

Project Title: Overcoming CAR T Resistance in Acute Myeloid Leukemia by Using Systemic Vaccination Project Description: This project aims to investigate the mechanisms by which a novel cancer vaccine enhances tumor rejection caused by genetically modified immune cells against acute myeloid leukemia. Genetically engineered immune cells have not yet shown great promise against this specific […]

Project Title: Recipient specific CAR-T cells for AML relapse after allogeneic hematopoietic stem cell transplantation Project Description: Bone marrow transplants are the best treatment for some leukemia patients, but there are few good treatments for leukemia that relapses after transplant. In this project, we exploit genetic differences between patients and their donors to make immune […]